AbbVie’s Rinvoq Scores Phase III Wins in Non-Segmental Vitiligo

AbbVie’s Rinvoq (upadacitinib) has achieved positive results in two Phase III Viti-Up trials (NCT06118411) for non-segmental vitiligo (NSV), potentially marking its eighth indication. The JAK inhibitor met its primary endpoint, with 19.4% and 21.5% of patients achieving a 50% reduction in total vitiligo area scoring index (T-VASI 50) across the two studies. Improvements were also seen in facial vitiligo, with 25.2% and 23.4% of participants reaching 75% facial clearance (F-VASI 75) at week 48.

Rinvoq met key secondary endpoints, achieving 50% facial clearance in nearly half of treated patients. Safety findings were consistent with prior studies, with mild adverse events like nasopharyngitis, upper respiratory infections, and acne.

If approved, Rinvoq would join Incyte’s Opzelura as one of the few targeted NSV therapies, competing with Pfizer’s Litfulo, now in Phase III. AbbVie’s success strengthens its immunology portfolio as it offsets Humira’s post-patent decline.

03-11-2025